

**AMENDMENTS TO THE CLAIMS**

1. (Previously Presented) A human antibody, comprising:  
human immunoglobulin VH-chain CDR1, CDR2, and CDR3 consisting of amino-acid sequences represented by SEQ ID NOS: 4, 5, and 6, respectively; and  
human immunoglobulin VL-chain CDR1, CDR2, and CDR3 consisting of amino-acid sequences represented by SEQ ID NOS: 10, 11, and 12, respectively.
2. (Previously Presented) A human antibody, comprising:  
a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 3;  
and  
a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 9.
3. (Previously Presented) A human antibody, comprising:  
ligation of a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 3; and  
ligation of a polypeptide consisting of an amino-acid sequence represented by SEQ ID NO: 9.
4. (Previously Presented) The human antibody according to any one of Claims 1 to 3, including amino-acid sequences, represented by SEQ ID NOS: 3 to 7 and 9 to 11, one or more amino acids of which are substituted, deleted, inserted, and/or added, and bind to human interleukin-18.
5. (Previously Presented) A human antibody, being a human anti-human interleukin-18 antibody against human interleukin-18, the human antibody having (1) binding activity to human interleukin-18 and (2) inhibitory activity for inhibiting physiological activity of human interleukin-18.
6. (Currently amended) A modified antibody, comprising the human antibody according to any one of Claims ~~1 to 5~~ 1-3 and 5 and a modification agent binding thereto.

7. (Previously Presented) A gene coding the human antibody according to any one of Claims ~~1 to 5~~ 1-3 and 5.

8. (Previously Presented) The gene according to Claim 7, including as an open reading frame a base sequence represented by SEQ ID NO: 1 or 7.

9. (Currently Amended) A recombinant expression vector, comprising the gene according to Claim 7 ~~or 8~~.

10. (Currently Amended) A transformant, comprising the gene according to Claim 7 ~~or 8~~ introduced therein.

11. (Currently Amended) A method for producing a human antibody against human interleukin-18 by causing a host to express the gene according to Claim 7 ~~or 8~~.

12. (Currently Amended) A detector for human interleukin-18, the detector using either (1) the antibody according to any one of Claims ~~1 to 5~~ 1-3 and 5, or (2) ~~the a~~ a modified antibody according to Claim 6 comprising the human antibody according to any one of Claims 1 to 5 and a modification agent binding thereto.

13. (Currently Amended) An immunological disease diagnostic kit for measuring an amount of human interleukin-18 contained in a test sample, by using either (1) the antibody according to any one of Claims ~~1 to 5~~ 1-3 and 5, or (2) a human interleukin-18 detecting reagent including ~~the a~~ a modified antibody according to Claim 6 comprising the human antibody according to any one of Claims 1-3 and 5 and a modification agent binding thereto.

14. (Previously Presented) A method for diagnosing immunological disease in accordance with an amount of human interleukin-18 contained in a test sample and measured by using the detecting reagent according to Claim 13.

15. (Previously Presented) A human interleukin-18 activity inhibitor, comprising a human interleukin-18 antagonist as an active ingredient.

16. (Currently Amended) The human interleukin-18 activity inhibitor according to Claim ~~18-15~~, wherein the human interleukin-18 antagonist is any one of following substances selected from:

- (i) the human antibody according to any one of Claims ~~1 to 5~~ 1-3 and 5;
- (ii) the a modified antibody according to Claim 6 comprising the human antibody according to any one of Claims 1-3 and 5 and a modification agent binding thereto; and
- (iii) a low-molecular compound obtained through molecular designing in accordance with an antigen determining region on human interleukin-18, the antigen determining region being recognized by either (1) the antibody according to (i), or (2) the modified antibody according to (ii).

17. (Currently Amended) A gene therapy agent, comprising the gene according to Claim ~~7 or 8~~.

18. (Currently Amended) A immunological disease treatment agent, comprising ~~either (1) the human interleukin-18 activity inhibitor according to Claim 15 or 16, or (2) the gene therapy agent according to Claim 17.~~

19. (Previously Presented) A method for treating immunological disease by administering the immunological disease treatment agent according to Claim 18.

20. (Previously Presented) The immunological disease treatment agent according to Claim 18, which inhibits cytokines produced from helper T1 cells stimulated with an antigen and human interleukin-18.

21. (Previously Presented) The immunological disease treatment agent according to Claim 18 or 20, which is applied to human interleukin-18-related allergy, inflammation, and chronic immune abnormality disease.

22. (Cancelled)

23. (Cancelled)

24. (Cancelled)

25. (New) A recombinant expression vector, comprising the gene according to Claim 8.

26. (New) A transformant, comprising the gene according to Claim 8 introduced therein.

27. (New) A method for producing a human antibody against human interleukin-18 by causing a host to express the gene according to Claim 8.

28. (New) A gene therapy agent, comprising the gene according to Claim 8.

29. (New) A immunological disease treatment agent, comprising the human interleukin-18 activity inhibitor according to Claim 16.

30. (New) A immunological disease treatment agent, comprising the gene therapy agent according to Claim 17.